History

June 2007

Established as a wholly owned subsidiary of STELLA CHEMIFA CORPORATION.

July 2008

Obtained the first-class marketing license for pharmaceuticals

November 2012

Started Phase I study of brain tumor in Japan with SPM-011(The target of brain tumor is patients with recurrent malignant glioma)

December 2013

Obtained the first-class marketing license for medical devices

January 2014

Relocated the research facility to the BNCT Research Center of Osaka Prefecture University for improving the efficiency of R&D

April 2014

Started Phase I study of head and neck cancer in Japan with SPM-011 (The target of head and neck cancer is patients with locally unresectable recurrent or unresectable advanced head and neck cancer (non-squamous epithelial cancer))

February 2016

Started Phase II study of brain tumor in Japan with SPM-011 (The target of brain tumors is patients with recurrent malignant glioma)

March 2016

With the underwriters of INCJ, Ltd. and Sumitomo Heavy Industries, Ltd., the capital was increased by a third-party allotment method (The voting rights holding ratio of Stella Chemifa Co., Ltd. has decreased to 64%)

July 2016

Started Phase II study of head and neck cancer in Japan with SPM-011 (The target of head and neck cancer is patients with locally unresectable recurrent or unresectable advanced head and neck cancer(non-squamous epithelial cancer)

April 2017

SPM-011 designated as a pharmaceutical product subject to the “SAKIGAKE Designation System” by the Ministry of Health, Labor and Welfare

May 2018

Opened Tokyo branch (Chuo-ku, Tokyo)

March 2020

Received marketing and manufacturing approval in Japan for STEBORONINE® 9000 mg/300 mL for infusion for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer

May 2020

Launched STEBORONINE® 9000 mg/300 mL for infusion in Japan